 |
|
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Christina A. Rabinak, BSE;
Melissa J. Nirenberg, MD, PhD
Arch Neurol. 2010;67(1):58-63.
Objectives To report and characterize a dopamine agonist (DA) withdrawal syndrome (DAWS) in Parkinson disease.
Design Retrospective cohort study.
Setting Outpatient tertiary movement disorders clinic.
Patients A cohort of 93 nondemented patients with Parkinson disease enrolled in a prospective study of nonmotor and motor disease manifestations.
Main Outcome Measure The presence of DAWS, defined as a severe, stereotyped cluster of physical and psychological symptoms that correlate with DA withdrawal in a dose-dependent manner, cause clinically significant distress or social/occupational dysfunction, are refractory to levodopa and other Parkinson disease medications, and cannot be accounted for by other clinical factors.
Results Of 40 subjects treated with a DA, 26 underwent subsequent DA taper. Of these 26 subjects, 5 (19%) developed DAWS and 21 (81%) did not. All subjects with DAWS had baseline DA-related impulse control disorders. Symptoms of DAWS resembled those of other drug withdrawal syndromes and included anxiety, panic attacks, agoraphobia, depression, dysphoria, diaphoresis, fatigue, pain, orthostatic hypotension, and drug cravings. Subjects with DAWS as compared with those without DAWS had higher baseline DA use (mean [SD], 420 [170] vs 230 [180] DA levodopa equivalent daily doses [DA-LEDD], respectively; P = .04) and higher cumulative DA exposure (mean [SD], 1800 [1200] vs 700 [900] DA-LEDD-years, respectively; P = .03). Subjects with DAWS also had considerably lower Unified Parkinson's Disease Rating Scale motor scores than those without DAWS (mean [SD], 21 [5] vs 31 [10], respectively; P = .007), despite comparable disease duration (mean [SD], 7.3 [7] vs 6.3 [4] years, respectively; P = .77) and similar total dopaminergic medication use (mean [SD], 830 [450] vs 640 [610] total LEDD, respectively; P = .52) in the 2 groups.
Conclusions Dopamine agonists have a stereotyped withdrawal syndrome that can lead to profound disability in a subset of patients. Physicians should monitor patients closely when tapering these medications.
Author Affiliations: Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Dopamine Agonist Withdrawal Syndrome: The Apomorphine Solution
Ilana Schlesinger, Ilana Erikh, and Menashe Zaaroor
Arch Neurol. 2010;67(9):1155.
EXTRACT
| FULL TEXT
Dopamine Agonist Withdrawal Syndrome: The Apomorphine Solution—Reply
Melissa J. Nirenberg and Christina A. Rabinak
Arch Neurol. 2010;67(9):1156.
EXTRACT
| FULL TEXT
Dopamine Agonists vs Levodopa in Impulse Control Disorders—Reply
Daniel Weintraub, Mandy Fraessdorf, Marc N. Potenza, Andrew D. Siderowf, Mark Stacy, Valerie Voon, Jacqueline Whetteckey, Glen R. Wunderlich, and Anthony E. Lang
Arch Neurol. 2011;68(4):545-546.
EXTRACT
| FULL TEXT
RELATED ARTICLE
This Month in Archives of Neurology
Arch Neurol. 2010;67(1):13-14.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Inpatient Management of Parkinson Disease: Current Challenges and Future Directions
Oguh and Videnovic
The Neurohospitalist 2012;2:28-35.
ABSTRACT
| FULL TEXT
Neurological diseases and pain
Borsook
Brain 2011;0:awr271v1-awr271.
ABSTRACT
| FULL TEXT
Network correlates of the cognitive response to levodopa in Parkinson disease
Mattis et al.
Neurology 2011;77:858-865.
ABSTRACT
| FULL TEXT
International Report: Local response following the Great East Japan Earthquake 2011
Meguro
Neurology 2011;77:e12-e15.
FULL TEXT
Dopamine Agonists vs Levodopa in Impulse Control Disorders--Reply
Weintraub et al.
Arch Neurol 2011;68:545-546.
FULL TEXT
Challenges of medication management in hospitalized patients with Parkinson's disease
Wood et al.
Am J Health Syst Pharm 2010;67:2059-2063.
FULL TEXT
Reply: Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery
Thobois et al.
Brain 2010;133:e156-e156.
FULL TEXT
Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery
Nirenberg
Brain 2010;133:e155-e155.
FULL TEXT
Dopamine Agonist Withdrawal Syndrome: The Apomorphine Solution--Reply
Nirenberg and Rabinak
Arch Neurol 2010;67:1156-1156.
FULL TEXT
Dopamine Agonist Withdrawal Syndrome: The Apomorphine Solution
Schlesinger et al.
Arch Neurol 2010;67:1155-1155.
FULL TEXT
|
